Genetic testing for kidney disease risk in African Americans
APOL1 Genetic Testing in African Americans: Exploring Attitudes About Genetic Risk to Improve Comprehensive Kidney Risk Assessment for Patients and Families
This study is trying to see if knowing about certain genetic risks for kidney disease helps African Americans with high blood pressure take better care of their health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | St. Louis University Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Trial ID | NCT05656261 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the prevalence of APOL1 renal risk variants among African American patients with hypertension at Saint Louis University. It aims to understand how knowledge of one's APOL1 genotype influences patient engagement in managing hypertension and other renal risk factors. Participants will complete self-administered surveys to express their attitudes towards genetic testing and its implications for kidney health. The study seeks to bridge the gap between genetic predisposition and clinical outcomes in chronic kidney disease.
Who should consider this trial
Good fit: Ideal candidates are Black or African American adults aged 18-90 who are seen in nephrology or hypertension clinics.
Not a fit: Patients who are cognitively impaired, terminally ill, or currently undergoing renal replacement therapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for kidney disease in African Americans by personalizing care based on genetic risk.
How similar studies have performed: Other studies have shown promise in using genetic testing to inform treatment strategies in chronic kidney disease, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ages 18-90 * Self-Identified as Black/African American. Race will be self-identified. Patients of African ancestry who identify as multi-racial are also eligible to participate. Exclusion Criteria: * Cognitively impaired/unable to provide consent * Terminally ill * Renal replacement therapy (RRT), e.g., (but not limited to) hemodialysis, peritoneal dialysis
Where this trial is running
St Louis, Missouri
- SSM Health Saint Louis University Hospital — St Louis, Missouri, United States (Recruiting)
Study contacts
- Study coordinator: Krista Lentine, PhD, MD
- Email: krista.lentine@health.slu.edu
- Phone: 314-257-3760
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.